Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.54 |
| ▸ | BCHE | P06276 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20175932 | 0.95 | BCHE (0.47) | ACHEBCHEKDM4EKDM4AKDM4C | |
| SCHEMBL20175931 | 0.90 | ACHE (0.52) | ACHEBCHEAKR1B1HSP90AA1MAPT | |
| SCHEMBL20175935 | 0.85 | BCHE (0.46) | ACHEBCHEKDM4EAKR1B1HSP90AA1 | |
| SCHEMBL20175933 | 0.80 | MAPT (0.55) | ACHEBCHEAKR1B1HSP90AA1APP | |
| SCHEMBL20175938 | 0.80 | BCHE (0.42) | ACHEBCHEKDM4EAKR1B1HSP90AA1 | |
| SCHEMBL17342246 | 0.78 | AKR1B1 (0.50) | KDM4ECHRM2AKR1B1APPMAPT | |
| SCHEMBL20175934 | 0.76 | BCHE (0.45) | ACHEBCHEHSP90AA1APPMAPT | |
| SCHEMBL15483822 | 0.75 | HTR1A (0.47) | CHRM2AKR1B1 | |
| SCHEMBL20175944 | 0.74 | MAPT (0.43) | ACHEBCHEHSP90AA1MAPT | |
| SCHEMBL21417964 | 0.72 | AKR1B1 (0.46) | AKR1B1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | FECH, SLC19A1, SLC40A1 | ACHE 1215/4885BCHE 1142/4885KDM4E 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.